- Trials with a EudraCT protocol (225)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
225 result(s) found for: Cervical Cancer Screening.
Displaying page 1 of 12.
EudraCT Number: 2020-001169-34 | Sponsor Protocol Number: HPV_Elimination | Start Date*: 2021-03-24 | ||||||||||||||||
Sponsor Name:Region Stockholm [...] | ||||||||||||||||||
Full Title: Concomitant HPV vaccination and HPV screening for rapid elimination of HPV infection and cervical cancer in Sweden | ||||||||||||||||||
Medical condition: HPV infection and related diseases, such as cervical intraepithelial neoplasia grade 2 and 3 and cervical cancer. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: SE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006946-24 | Sponsor Protocol Number: NV25025 | Start Date*: 2009-12-10 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5x10E7pfu RO5217790 in patients with high... | ||||||||||||||||||
Medical condition: High grade cervical intraepithelial neoplasia grade 2 or 3 associated with High Risk HPV infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) FI (Completed) ES (Completed) BE (Completed) | ||||||||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2022-000269-42 | Sponsor Protocol Number: 1-23-456 | Start Date*: 2022-06-08 | |||||||||||
Sponsor Name:Randers Regional Hospital, Department of Gynecology and Obstetrics | |||||||||||||
Full Title: Improving diagnostics in cervical dysplasia | |||||||||||||
Medical condition: Abnormal cervical cells | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003177-42 | Sponsor Protocol Number: COHEAHR-WP4 | Start Date*: 2014-10-10 | ||||||||||||||||
Sponsor Name:Catalan Institute of Oncology | ||||||||||||||||||
Full Title: Multinational study assessing the acceptability and determinants of compliance to HPV vaccination to women in screening ages 30 to 45 years | ||||||||||||||||||
Medical condition: Cervical cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: DK (Completed) ES (Completed) BE (Completed) FI (Completed) SI (Completed) NL (Completed) SE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-003507-19 | Sponsor Protocol Number: HOPE9 | Start Date*: 2020-09-10 | |||||||||||||||||||||
Sponsor Name:AZIENDA USL TOSCANA NORD OVEST | |||||||||||||||||||||||
Full Title: “Phase III, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy of pre-surgical HPV 9-valent vaccination in women treated with electrosurgical excision with diat... | |||||||||||||||||||||||
Medical condition: Prevention of recurrence after a first episode of high-grade cervical intraepithelial neoplasia (CIN2 +) up to initially invasive cervical cancer (FIGO IA1) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003413-25 | Sponsor Protocol Number: GCT1015-04 | Start Date*: 2018-03-07 | |||||||||||
Sponsor Name:Genmab A/S | |||||||||||||
Full Title: A single arm, multicenter, international trial of tisotumab vedotin (HuMax®-TF-ADC) in previously treated, recurrent or metastatic cervical cancer | |||||||||||||
Medical condition: recurrent or metastatic cervical cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: CZ (Completed) DK (Completed) BE (Completed) DE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005578-12 | Sponsor Protocol Number: 08-PIR-06 | Start Date*: 2009-03-02 | |||||||||||
Sponsor Name:Nektar Therapeutics | |||||||||||||
Full Title: A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Locally Advanc... | |||||||||||||
Medical condition: Patients with Metastatic or Locally Advanced Cervical Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002328-33 | Sponsor Protocol Number: VB_C-02 | Start Date*: 2020-02-07 | |||||||||||
Sponsor Name:Nykode Therapeutics ASA | |||||||||||||
Full Title: A Multi-Centre, Open-label Phase 2a Trial of the Combination of VB10.16 and Atezolizumab in Patients with Advanced or Recurrent, Non-resectable HPV16-Positive Cervical Cancer | |||||||||||||
Medical condition: Advanced or recurrent non-resectable HPV16-positive cervical cancer, who failed or are not eligible for current standard of care | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) NO (Completed) BG (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000236-27 | Sponsor Protocol Number: VEG105281 | Start Date*: 2006-12-15 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination with Lapatinib (GW572016) Compared to Pazopanib Montherapy and Lapatinib Monotherapy in Subjects with FI... | |||||||||||||
Medical condition: Patients with FIGO Stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) IE (Completed) FR (Completed) EE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001655-39 | Sponsor Protocol Number: GCT1015-07 | Start Date*: 2021-08-17 | |||||||||||
Sponsor Name:Genmab A/S | |||||||||||||
Full Title: A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin Versus Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer | |||||||||||||
Medical condition: Second- or Third-Line Recurrent or Metastatic Cervical Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) NO (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned) BE (Ongoing) AT (Trial now transitioned) DK (Completed) NL (Trial now transitioned) PL (Trial now transitioned) IT (Ongoing) DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003583-40 | Sponsor Protocol Number: MS200647_0017 | Start Date*: 2020-07-07 | |||||||||||
Sponsor Name:Merck Healthcare KGaA | |||||||||||||
Full Title: A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with Advanced, Unresectable Cervical Cancer with Disease Progression During or After Platinum-Contai... | |||||||||||||
Medical condition: Cervical Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) ES (Ongoing) HU (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003447-11 | Sponsor Protocol Number: C-145-04 | Start Date*: 2017-10-27 | |||||||||||
Sponsor Name:Iovance Biotherapeutics, Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma | |||||||||||||
Medical condition: Recurrent, metastatic, or persistent Cervical Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005576-28 | Sponsor Protocol Number: VB-C-01 | Start Date*: 2015-07-13 |
Sponsor Name:VACCIBODY A.S. | ||
Full Title: An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women with High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3) | ||
Medical condition: High grade cervical intraepithelial neoplasia (HSIL, CIN 2/3) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-002918-19 | Sponsor Protocol Number: VEG110190 | Start Date*: 2007-09-06 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithkline Research & Development Limited | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase II, Open-Label, Multicenter Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women with Previously Untreated, Advanced Gynaecological Tumors | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: previously untreated, advanced gynaecological tumors | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) FR (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-002061-30 | Sponsor Protocol Number: 4.0 | Start Date*: 2016-07-18 | ||||||||||||||||||||||||||
Sponsor Name:University Hospital Southampton NHS Foundation Trust | ||||||||||||||||||||||||||||
Full Title: Therapeutic HPV vaccine trial +/- anti-CD40 in HPV-driven squamous cell carcinoma. | ||||||||||||||||||||||||||||
Medical condition: HPV induced cancers such as Head and Neck Squamous Cell Carcinoma (HNSCC), Anogenital Cancer, Cervical Cancer, Penile Cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004277-31 | Sponsor Protocol Number: E012-HPV | Start Date*: 2021-12-23 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:eTheRNA immunotherapies NV | ||||||||||||||||||||||||||||||||||||||
Full Title: A phase I/IIa open label study to assess the safety, tolerability, immunogenicity and clinical activity of EI-201 mRNA immunotherapy given intravenously in subjects with recurrent or metastatic HPV... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Incurable recurrent or metastatic (R/M) HPV16-positive (HPV16+) tumors (e.g. oropharyngeal cancer, cervical, vulvar, vaginal, anal, penile cancer, etc.) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Ongoing) DE (Ongoing) PL (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000367-83 | Sponsor Protocol Number: ENGOT-Cx10/GEICO68-C/BEATcc | Start Date*: 2018-08-08 | |||||||||||
Sponsor Name:Grupo Español de Investigación en Cáncer de Ovario (GEICO) | |||||||||||||
Full Title: A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persi... | |||||||||||||
Medical condition: Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) NO (Ongoing) SE (Ongoing) DE (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004050-29 | Sponsor Protocol Number: Vvax001-UMCG-02 | Start Date*: 2020-03-30 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: A phase II study to determine the efficacy and safety of Vvax001, a therapeutic Semliki Forest Virus based cancer vaccine, in patients with HPV-16 induced grade 3 cervical intraepithelial neoplasia. | ||
Medical condition: HPV-16 induced pre malignant cervical lesions | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003172-12 | Sponsor Protocol Number: KY1044-CT01 | Start Date*: 2019-03-07 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Kymab Ltd | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 1/2, open-label, multi-center study of the safety and efficacy of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Advanced/metastatic malignancies, and preferred indications: head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), esophageal cancer, ga... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Ongoing) HU (Ongoing) PL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006543-10 | Sponsor Protocol Number: XB002-101 | Start Date*: 2023-03-27 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Exelixis, Inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Advanced solid tumors for whom life-prolonging therapies do not exist or available therapies are intolerable or no longer effective. Single-agent XB002 will be evaluated up to 10 tumor types, and c... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.